ITOC is the ticker for iTonic Holdings Ltd., a Nasdaq Capital Market–listed healthcare technology company (formerly Pheton Holdings Ltd., rebranded in January 2026). The Beijing-based holding company develops treatment-planning software and devices for brachytherapy, a form of targeted radiation therapy. Unlike larger, widely followed names, ITOC is a nano-cap with essentially no credible sell-side price-target coverage, which makes any "price forecast" a question of valuation and technical context rather than a published analyst consensus.
Because ITOC lacks a meaningful pool of current analyst price targets, the usual method of averaging individual targets cannot be applied. MarketBeat reports a "N/A" consensus target, and price-target aggregators list no active Wall Street targets for the stock. The only tracked opinion is a "Sell" rating from Weiss Ratings, which does not provide a conventional 12-month price objective.
For that reason, the $3.20 level used here comes from a valuation anchor rather than an analyst consensus. The company's reported book value per share is approximately $3.22, and the stock has traded below that figure, implying a price-to-book (P/B) ratio of roughly 0.81. A return to book value serves as a defensible, publicly observable reference point, and it is rounded to $3.20 for clarity. This is a benchmark for discussion, not a forecast or a guarantee.
The latest verified close for ITOC is near $2.60, well off its 52-week high of $18.40 and just above its 52-week low of $2.12. Reaching $3.20 would require a move of roughly 23%, which is substantial for a low-liquidity micro-cap, though the stock has shown far larger swings in both directions over the past year.
The path would most plausibly depend on fundamental progress: evidence of growing revenue from its brachytherapy planning software (flagship product FTTPS), a path toward reduced losses, and clarity on its Nasdaq listing-compliance status. With negative EPS (earnings per share) over the trailing twelve months and a negative price-to-earnings ratio, any re-rating would likely be driven by operational milestones and sentiment rather than current profitability.
The chart is dominated by a severe decline from the 52-week high of $18.40 toward the $2.12 low. The $2.12 level stands out as a critical support zone, while the recent trading band between roughly $2.10 and $2.90 represents near-term congestion. The $3.00 level is a psychological round number, and the $3.20 book-value benchmark sits just above it. On the upside, any durable move beyond the low-$3.00 area would encounter far less visible resistance, given how far the stock has already fallen from its peak.
Because no analyst target exists, there is no standardized research horizon attached to the $3.20 benchmark; it should be viewed as a valuation reference rather than a dated forecast. Investors should monitor the company's quarterly filings for revenue growth and loss trends, any Nasdaq compliance announcements, capital-raising activity, and updates on the AI home-care platform. Given the stock's volatility, the path toward or away from $3.20 is likely to be event-driven rather than gradual.
For traders seeking a more systematic read on ITOC and thousands of other securities, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. These tools can help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening alone. Traders looking for an edge may want to explore these AI-generated signals as part of a broader research routine.
The $3.20 target is not a consensus forecast but a valuation benchmark anchored to ITOC's roughly $3.22 book value per share. With the stock near $2.60, reaching that level would require a substantial gain of about 23%. The case for the move rests on a below-book valuation and a credible product and platform story, while the case against it is grounded in ongoing losses, minimal revenue, nano-cap liquidity, and listing-compliance uncertainty. Because there are no credible analyst targets to provide a range of opinions, investors should treat $3.20 as a framework for monitoring fundamentals rather than as a predicted outcome.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that ITOC and PFSA have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ITOC and PFSA's prices will move in lockstep.
| Ticker / NAME | Correlation To ITOC | 1D Price Change % | ||
|---|---|---|---|---|
| ITOC | 100% | -17.35% | ||
| PFSA - ITOC | 30% Poorly correlated | +1.84% | ||
| PEN - ITOC | 29% Poorly correlated | +0.47% | ||
| APYX - ITOC | 25% Poorly correlated | -2.54% | ||
| MYO - ITOC | 22% Poorly correlated | -4.23% | ||
| NEOG - ITOC | 21% Poorly correlated | +1.65% | ||
More | ||||
| Ticker / NAME | Correlation To ITOC | 1D Price Change % |
|---|---|---|
| ITOC | 100% | -17.35% |
| Health Services category (238 stocks) | 4% Poorly correlated | -1.47% |
| Medical/Nursing Services category (138 stocks) | 4% Poorly correlated | -0.57% |